RSS   Newsletter   Contact   Advertise with us

Acacia Pharma non-executive chairman Ian Kent to retire

Staff writer | Cambridge, United Kingdom | December 4, 2015
Acacia PharmaDecember 4, 2015, Cambridge, United Kingdom - Acacia Pharma Group plc, a specialty pharmaceutical company, announces that Ian Kent will retire as non-executive chairman.
Dr. Vink most recently served as chief operating officer of Cubist Pharmaceuticals, joining there from senior roles at Mylan Inc., including having global responsibility for the group’s hospital business.

Previously Dr. Vink held several leadership positions with Novartis Sandoz, Sanofi and Biogen, principally in global commercial roles. He is also a non-executive director of Inhibikase Inc. and Micreos BV.

He will be succeeded by Patrick Vink on December 31, 2015.

Mr. Kent joined the Company as non-executive Chairman in February 2009 and is Chairman of the Nomination Committee. He has been chairman and non-executive director of a number of successful public and private life sciences companies.

He is currently chairman of Pulmagen Therapeutics Ltd. He was previously founder, chairman and executive director of Imutran Ltd, which was sold to Novartis in 1997. In addition, he was chairman of Innovata plc, which was sold to Vectura Group plc in 2007 and PIramed, sold to Roche in 2008.

His previous non-executive appointments include Vernalis plc, Biofocus plc, Adprotech Ltd, LGC Holdings and Roslin Biomed Ltd.

 LATEST MOVES FROM The United Kingdom